Skip to main content
OpenTrials
Completed

NCT Number: NCT03809598

Roo Study on Mom and Baby Well-Being

This study employs a randomized controlled trial of an established intervention, Mindfulness Based Cognitive Therapy (MBCT) adapted for pregnancy, to examine effects on various aspects of maternal psychological stress during pregnancy (magnitude and trajectories of stress) and offspring brain systems integral to healthy and maladaptive emotion regulation. This study considers other potential influences on maternal stress and psychiatric symptomatology, and infant behavior and brain development. The study population is pregnant women aged 21-45, and their infants.

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 day–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Oregon Health and Science University

Portland, Oregon, 97239, United States

About this study

The study will involve an online screen of potentially eligible pregnant women. If women are eligible after the online screen, they will be invited in for an in-person assessment, including cognitive testing and a diagnostic interview, to further determine eligibility. After the assessment, they will be informed of their eligibility status and, if applicable, randomized to a Mindfulness Based Cognitive Therapy (MBCT) group involving an 8-session group-based intervention or to treatment as usual (TAU) during pregnancy followed by one mindfulness psychoeducation session postpartum. Eligible participants will then be invited in for a study visit during which they will give blood, urine, and saliva samples. Participants in the MBCT group will complete questionnaires prior to the 1st group session, after the 4th session, and after the 8th/final session. Participants in the TAU group will complete the same questionnaires at equivalent time points. All participants will come in for an in-person session at 34 weeks GA, during which they will complete questionnaires, a brief clinical interview and provide blood, urine, and saliva samples again. Participants will then come in with their infant for the infant MRI scan within one month of giving birth. Study staff will collect a hair and saliva sample from the infant at this time. Participants will have a remote visit at 6 weeks postpartum, during which time they will complete questionnaires and a clinical interview. At 6 months postpartum, participants will return for their final visit, during which they will complete questionnaires and a clinical interview. Mothers and infants will also provide a hair sample at this time. Some visits will be adapted as needed to accommodate institutional requirements with regard to restrictions due to COVID-19.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Pregnant Women/ Mothers:

Inclusion and exclusion criteria for pregnant women/ mothers will be determined by a combination of the initial screen and intake assessment.

Inclusion criteria

include:

  • be 21-45 years old
  • be a female who is currently pregnant (8-22 weeks GA at screening)
  • fluently speak English
  • be available and physically able to attend group scheduled meetings
  • have a single gestation, and
  • have a history of an internalizing psychiatric disorder.

Exclusion criteria

include:

  • Major neurological or medical condition (e.g., diabetes, MS),
  • IQ <80
  • maternal use of psychotropic medications, insulin, or any other medications that might impact the central nervous system (at the time of enrollment)
  • current diagnosis of substance use disorder, illicit drug use or nicotine use
  • diagnosis of autism, developmental disorder involving intellectual disability or a psychotic disorder
  • current major depressive episode, eating disorder or manic episode
  • current active suicidality and/or homicidally, or interpersonal violence
  • prior history of engaging in mindfulness-based psychotherapeutic interventions (e.g., MBCT, MBSR, DBT (mindfulness module))
  • pregnancy-specific medical conditions or complications including placental abnormality or other conditions requiring bed rest
  • known congenital, genetic, or neurologic disorder of the fetus (e.g., Down syndrome, fragile X)
  • uncorrectable vision or hearing impairments (including color blindness)

Infants:

Inclusion for infants to participate in MRI scan include:

  • being between 37 and 50 weeks gestational age (GA) equivalent at time of 1st scan*
  • not meeting any of the exclusion criteria below.
  • We are using GA equivalent rather than postnatal age because infants born pre-term will not be scanned prior to term equivalent (37 weeks GA). Therefore, infants who are born preterm may be older in terms of postnatal age, but will be similar to infants born at term with regard to time since conception. The time since conception is more pertinent to our measures of brain development versus postnatal age.

Exclusion criteria

for infants (specifically exclusionary for MRI scan) include:

  • congenital, genetic, or neurologic disorder (e.g., Down syndrome, fragile X)
  • major neurologic disorder at birth (e.g., bacterial meningitis, epilepsy)
  • birth < 30 weeks GA
  • medical complications following birth requiring ongoing hospitalization.
  • medical complications or health problems at or following birth, which could make an MRI scan unsafe or uncomfortable

Treatment and study plan

Mindfulness Based Cognitive Therapy

Behavioral

See "Mindfulness Based Cognitive Therapy (MBCT) Arm" description

Other names: Mindfulness Based Cognitive Therapy for Perinatal Depression

Primary outcomes

  1. Maternal Psychological Stress

    Time frame: Intake - 34 Weeks GA (T5)

    Maternal psychological stress will be a composite of the Perceived Stress Scale (PSS), Beck Anxiety Inventory (BAI), and Pregnancy Distress Questionnaire (PDQ) The magnitude and trajectory of maternal psychological stress will be examined.

  2. Maternal Depression

    Time frame: Intake - 34 Weeks GA (T5)

    Maternal depressive symptoms will be measured using the Center for Epidemiologic Studies Depression Scale - Revised (CESD-R). The magnitude and trajectory of maternal psychological stress will be examined.

Secondary outcomes

  1. Blood assay for inflammatory marker IL6

    Time frame: 34 Weeks GA (T5)

    Levels of IL6 assayed from maternal blood samples. Difference in magnitude of inflammation between groups at T5 after adjusting for inflammation prior to the intervention.

  2. Maternal Cortisol

    Time frame: 34 Weeks GA (T5)

    The cortisol levels obtained from participant's hair samples to assess cumulative cortisol from pre- to post-intervention.

  3. Neonatal Resting State fMRI scan

    Time frame: Infant Scan (T6)

    MRI scans with neonates will occur during natural sleep. Resting state functional connectivity will be the outcome of interest.

  4. Neonatal Structural MRI scan

    Time frame: Infant Scan (T6)

    MRI scans with neonates will occur during natural sleep. Neonatal subcortical brain structure volume will be the outcome of interest.

  5. Maternal Pregnancy Specific Psychological Stress

    Time frame: Intake - 34 weeks (T5)

    The Prenatal Distress Questionnaire (PDQ) is a short measure designed to assess specific worries and concerns related to pregnancy.

Sponsors and collaborators

Lead sponsor

Oregon Health and Science University

Other

Registry information

Official study title

A Targeted Approach to Examine the Influence of Maternal Psychological Stress on Newborn Brain Outcomes

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Jan 18, 2019
Registry last updated
Sep 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.